Popular Stories

PULM Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Energy
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Pulmatrix Soars on News of Licensing Agreement with Johnson & Johnson

Pulmatrix Inc (NASDAQ: PULM), a Clinical Stage Biopharmaceutical Company developing inhaled therapies for the treatment of pulmonary diseases, announced the signing of a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (NYSE: JNJ), enabling the initiative to access the Company’s...

New therapeutics promise respite to patients suffering from COPD

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and irreversible degeneration of the lungs which is characterised by difficulty in breathing and poor airflow and manifests itself as diseases such as emphysema, chronic bronchitis and refractory (non-reversible) asthma. The World Health Organization (WHO) estimates that there...

CAN GENE THERAPY AND RNA TECHNOLOGY COMBAT CYSTIC FIBROSIS?

Cystic Fibrosis is a chronic genetic disorder of the mucus glands that affects 2,500 newborns each year in the U.S.  30,000 people are currently affected by this disease and about 1 in 20 or roughly 12 million Americans are carriers of the “CF” gene and are unaware of...

WordPress Video Lightbox Plugin